PLRZ

Raanana, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission (the "SEC"). The report is available on the SEC's website, at www.sec.gov and Polyrizon’s Investor Relations website, at https://investor.polyrizon-biotech.com/. Shareholders can obtain copies of Polyrizon’s Annual Report on Form 20-F, free of charge, by making a request within a reasonable period of time to Polyrizon’s Investor Relations Department at [email protected]. About Polyrizon Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com. Forward Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by thei...

Raanana, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions today announced positive results from a new in-vitro pre-clinical study evaluating the allergen-blocking performance of its PL-14 Allergy Blocker formulation compared to hydroxypropyl methylcellulose (HPMC), an accepted and standard comparator used in nasal barrier products. The study, conducted using a validated in-vitro Transwell permeability system designed to mimic allergen transfer into the nasal mucosa, assessed PL-14’s ability to inhibit transfer of Der p 1, a major clinically relevant house dust mite allergen commonly associated with allergic rhinitis and asthma. Key findings demonstrated that PL-14 significantly reduced allergen transfer at all time points compared with HPMC, including early time points that are considered critical for preventing allergen-triggered immune activation. Statistical analysis showed that PL-14 significantly reduced Der p 1 transfer compared with HPMC at every tested time point (1, 2, 4, 6, and 24 hours), with p-values ≤ 0.0042. Highlights from the Study PL-14 showed markedly lower allergen transfer versus HPMC throughout the experiment, supporting a consistent barrier effect. At 1 hour, PL-14 demonstrated very low allergen penetration, with measured mean concentrations of ~20.6 ng compared with ~1354.4 ng for HPMC. HPMC exhibited substantial and time-dependent allergen permeation, rising to mean concentrations of ~5201.2 ng at 24 hours, consistent with limited barrier function. PL-14 maintained low mean allergen levels across all time points, reaching a maximum mean value of ~141.2 ng at 4 hours, supporting a sustained protective effect. “These results reinforce our belief that PL-14 can form an effective intranasal hydrogel barrier capable of reducing allergen exposure to nasal tissue,” said Tomer Izraeli, CEO of Polyrizon. “Importantly, this study benchmarked PL-14 against HPMC, an accepted comparator, and demonstrated statistically significant reduction in allergen transfer at all evaluated time points. From an R&D standpoint, we believe that this is an important confirmation of the performance of the PL-14 formulation using a rigorous quantitative permeation model. The data support continued advancement of...

Superior Mucoadhesion may potentially Translate into More Reliable Opioid Overdose Reversal in Real-World Emergencies Ra’anana, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced compelling new preclinical data showing its proprietary naloxone hydrogel adheres to nasal tissue longer than an approved and marketed intranasal naloxone spray product. Using an established ex-vivo rabbit nasal mucosa model, researchers evaluated the persistence of Polyrizon’s hydrogel formulation versus commercial product by applying each formulation to mucosal tissue and washing with Simulated Nasal Electrolyte Solution (SNES) over a 30-minute period. Quantification of residual fluorescence revealed that Polyrizon’s hydrogel maintained higher values of the fluorescence marker when compared to the commercial product, with differences reaching high statistical significance (p < 0.0001, two-way ANOVA), indicating notably stronger and more durable mucosal retention. The results showed that Polyrizon’s Trap and Target ™ (T&T) hydrogel exhibited significantly higher mucoadhesion levels compared to the commercial product, supporting potentially prolonged contact at the nasal deposition site and potentially enhancing bioavailability. Improved mucoadhesion is a critical factor for intranasal drug delivery - particularly for emergency treatments such as opioid overdose reversal - because enhanced residence time at the nasal deposition site can support more reliable absorption and potentially faster onset of action. “We believe that these outcomes further validate the potential of our T&T hydrogel platform and highlight its unique advantages in intranasal drug delivery,” said Tomer Izraeli, CEO of Polyrizon. “The ability to significantly outperform an existing marketed product in mucoadhesion is an important milestone as we continue advancing our Naloxone program.” This new dataset builds directly on the previously reported encouraging stability results, which demonstrated the robustness of Polyrizon’s formulation under various storage conditions. Collectively, stability plus mucoadhesion performance reinforce the potential of Polyrizon’s T&T technology to deliver a safer, more reliable, and more effective intranasal Naloxone product. About Polyriz...

Ra’anana, Israel, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company developing intranasal products based on its proprietary Capture & Contain (C&C) platform, today announced encouraging results from a recent pre-clinical study evaluating the allergen-blocking performance of its PL-14 Allergy Blocker formulation. The study was designed to simulate allergen exposure conditions and assess the ability of PL-14 to prevent allergen penetration through a hydrogel barrier. In the pre-clinical study, Der p 1 allergen, a major house dust mite allergen, was applied atop the PL-14 formulation. Samples were collected beneath the formulation at multiple time points to measure the quantity and pace of allergen penetration. The results demonstrated that PL-14 effectively limited allergen diffusion over time, forming an effective nasal barrier against the house dust mite allergen (Der p 1). Key results include: After one hour: Only 1.07% of the allergen passed through. After two hours: Penetration remained minimal at 1.14%. After four hours: Still highly effective, with just 13.6% diffusion. These findings emphasize the potentially strong barrier properties of PL-14, particularly during the critical early hours of exposure when allergen contact is most likely to trigger immune responses. Importantly, the allergen load used in this study was estimated to be tens of times higher than typical real-world exposure levels during allergy seasons, based on published clinical studies conducted in controlled allergen challenge chambers. This suggests that PL-14 may offer robust protection even under extreme allergen conditions. According to a Future Market Insights report, the Allergy Immunotherapy market is poised for substantial growth, with market valuation projected to increase from USD 1.9 billion in 2025 to USD 4.2 billion by 2035, expanding at a CAGR of 7.9% during the forecast period. This growth is primarily driven by the increasing prevalence of allergies worldwide, along with advancements in treatment methodologies and rising awareness of immunotherapy as an effective long-term solution. “Our innovative C&C platform is designed to form a protective hydrogel layer that captures and contains airborne allergens before they reach the nasal mucosa,” said Tomer Izraeli, CEO of Polyrizon. “We believe that these...

Ra’anana, Israel, June 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a biotechnology company developing intranasal drug delivery systems, today announced encouraging preclinical results from a recent study evaluating its proprietary hydrogel-based Trap & Target (T&T) platform. The study, conducted in collaboration with the University of Parma (Italy), demonstrated that Polyrizon’s hydrogel formulation achieves targeted deposition in the upper regions of the nasal cavity—critical for central nervous system (CNS) drug delivery. The promising results are part of a collaborative study between the Company and the Department of Food and Drug of the University of Parma (Italy), led and conducted by Professor Fabio Sonvico, a leading expert in the development of intranasal and pulmonary drug delivery solutions and a member of the Company’s Scientific Advisory Board. Using a silicone-based human nasal cast and fluorescein-traced imaging, the Polyrizon hydrogel formulation was shown to exhibit a preferential accumulation of over 60% in the middle and upper turbinates, the region’s most favorable for nose-to-brain transport. This region-specific delivery has the potential to be particularly promising for CNS indications, such as opioid overdose (e.g., naloxone) and benzodiazepine for epileptic seizures, where rapid and direct access to the brain can be lifesaving. “The results validate the unique capabilities of our T&T technology in achieving localized deposition in anatomically favorable zones of the nasal cavity,” said Tomer Izraeli, CEO at Polyrizon. “We believe that this has the potential to open a strategic path forward for leveraging our intranasal platform in the development of therapies for acute neurological and psychiatric conditions.” Polyrizon’s hydrogel demonstrated consistent, concentrated delivery to the upper nasal segments while maintaining favorable handling characteristics. These findings support the continued preclinical development of the T&T platform for CNS-targeted applications. Polyrizon intends to further validate these results in animal models and initiate safety studies as part of its translational roadmap for the T&T technology. About Polyrizon Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sp...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a collaboration LOI and a study publication. Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses. EARNINGS: On Monday, atai Life Sciences (ATAI) reported a fourth quarter loss per share of (24c) on revenue loss of ($5,000), which compared to analyst estimates of a loss per share of (15c) and revenue of $18,000 for the same period last year. As of December 31, the company had cash, cash equivalents, restricted cash and short-term securities of $72.3M compared to $154.2M as of December 31, 2023. In February, the company completed an equity offering with net proceeds of $59.2M and now expects its cash, short-term securities, and public equity holdings to be sufficient to fund operations into 2027. “We are beginning the year in a strong financial position, thanks to the recent capital raise, which extends our runway into 2027, beyond when we expect the topline data readouts from the Phase 2 clinical trials of our two core programs, VLS-01 and EMP-01, in 1Q26” stated Srinivas Rao, CEO. “Our team is focused on executing these trials rigorously and efficiently to drive forward our mission to transform patient outcomes in mental health. We also look forward to several key milestones this year, notably Beckley Psytech’s BPL-003 Phase 2b topline results in patients with treatment-resistant depression as well as RL-007 in patients with cognitive impairment associated with schizophrenia, both expected mid-2025.” Additionally on Monday, NRx Pharmaceuticals (NRXP) reported a FY24 loss per share of ($2.36), which compared to a loss per share of ($3.98) for the same period last year. As of December 31, the company had approximately $1.4M in cash and cash equivalents. In January, the company completed two financings with aggregate gross proceeds of approximately $8.5M. Management believes that current available cash resources will be sufficient to support ongoing operations through at least the end of 2025. “Our work in the fourth quarter of 2024 and into 2025 has driven significant advances for our company and investors. We have retired debt that was impeding the launch of HOPE Therapeutics and brought new investors into the Company who are aligned with our objectives. We launched the fili...